Advertisement

Oncology Navigation Decreases Time to Treatment in Patients with Pancreatic Malignancy

  • Laura M. Enomoto
  • Joyce Fenstermaker
  • Rodwige J. Desnoyers
  • Boris C. Pasche
  • A. William BlackstockJr.
  • Russell M. Howerton
  • Clancy J. Clark
  • Edward A. Levine
  • Perry ShenEmail author
Pancreatic Tumors

Abstract

Background

Care of pancreatic cancer patients has become increasingly complex, which has led to delays in the initiation of therapy. Nurse navigators have been added to care teams, in part, to ameliorate this delay. This study investigated the difference in time from first oncology visit to first treatment date in patients with any pancreatic malignancy before and after the addition of an Oncology Navigator.

Methods

A single-institution database of patients with any pancreatic neoplasm evaluated by a provider in radiation, medical, or surgical oncology between 1 October 2015 and 30 September 2017 was analyzed. After 1 October 2016, an Oncology Navigator met patients at their initial visit and coordinated care throughout treatment. The cohort was divided into two groups: patients evaluated prior to the implementation of an Oncology Navigator and patients evaluated after implementation. Patient demographics and time from first visit to first intervention were compared.

Results

Overall, 147 patients with a new diagnosis of pancreatic neoplasm were evaluated; 57 patients were seen prior to the start of the Oncology Navigator program and 79 were evaluated after the navigation program was implemented. On univariate analysis, time from first contact by any provider to intervention was 46 days prior to oncology navigation and 26 days after implementation of oncology navigation (p = 0.005). While controlling for other covariates, employment of the Oncology Navigator decreased the time from first contact by any provider to intervention by almost 16 days (p = 0.009).

Conclusions

Implementing an oncology navigation program significantly decreased time to treatment in patients with pancreatic malignancy.

Notes

Author Contributions

Conceptualization: PS. Data acquisition: LME, JF, RJD, BCP, AWB, RMH, CJC, EAL, PS. Data analysis and interpretation: LME, PS. Drafting of the manuscript: LME, PS. Editing and final approval of manuscript: LME, JF, RJD, BCP, AWB, RMH, CJC, EAL, PS

Funding

No specific funding was received for the conduct of this study or the preparation of this article.

Disclosure

Laura M. Enomoto, Joyce Fenstermaker, Rodwige J. Desnoyers, Boris C. Pasche, A. William Blackstock Jr, Russell M. Howerton, Clancy J. Clark, Edward A. Levine, and Perry Shen have no conflicts of interest to disclose.

References

  1. 1.
    Cancer Stat Facts: Pancreatic Cancer. https://seer.cancer.gov/statfacts/html/pancreas.html. Accessed May 2018.
  2. 2.
    McKenna LR, Edil BH. Update on pancreatic neuroendocrine tumors. Gland Surg. 2014;3(4):258–75.Google Scholar
  3. 3.
    Khan S, Sclabas G, Reid-Lombardo KM. Population-based epidemiology, risk factors and screening of intraductal papillary mucinous neoplasm patients. World J Gastrointest Surg. 2010;2(10):314–8.CrossRefGoogle Scholar
  4. 4.
    Jones RV, Greenwood B. Breast cancer: causes of patients’ distress identified by qualitative analysis. Br J General Pract. 1994;44(385):370–1.Google Scholar
  5. 5.
    Rapoport Y, Kreitler S, Chaitchik S, Algor R, Weissler K. Psychosocial problems in head-and-neck cancer patients and their change with time since diagnosis. Ann Oncol. 1993;4(1):69–73.CrossRefGoogle Scholar
  6. 6.
    Gray RE, Fitch MI, Phillips C, Labrecque M, Klotz L. Presurgery experiences of prostate cancer patients and their spouses. Cancer Pract. 1999;7(3):130–5.CrossRefGoogle Scholar
  7. 7.
    Bilimoria KY, Ko CY, Tomlinson JS, et al. Wait times for cancer surgery in the United States: trends and predictors of delays. Ann Surg. 2011;253(4):779–85.CrossRefGoogle Scholar
  8. 8.
    Institute of Medicine (US) Committee on Quality of Health Care in America. Crossing the quality chasm: a new health system for the 21st century. Washington (DC): National Academies Press (US); 2001.Google Scholar
  9. 9.
    Freund KM, Battaglia TA, Calhoun E, et al. National Cancer Institute Patient Navigation Research Program: methods, protocol, and measures. Cancer. 2008;113(12):3391–9.CrossRefGoogle Scholar
  10. 10.
    Rosenberg K. Patient navigators improve colorectal cancer screening rates. Am J Nurs. 2011;111(10):15.CrossRefGoogle Scholar
  11. 11.
    Basu M, Linebarger J, Gabram SG, Patterson SG, Amin M, Ward KC. The effect of nurse navigation on timeliness of breast cancer care at an academic comprehensive cancer center. Cancer. 2013;119(14):2524–31.CrossRefGoogle Scholar
  12. 12.
    Luckett R, Pena N, Vitonis A, Bernstein MR, Feldman S. Effect of patient navigator program on no-show rates at an academic referral colposcopy clinic. J Womens Health (Larchmt). 2015;24(7):608–15.CrossRefGoogle Scholar
  13. 13.
    Ell K, Vourlekis B, Lee PJ, Xie B. Patient navigation and case management following an abnormal mammogram: a randomized clinical trial. Prev Med. 2007;44(1):26–33.CrossRefGoogle Scholar
  14. 14.
    Battaglia TA, Roloff K, Posner MA, Freund KM. Improving follow-up to abnormal breast cancer screening in an urban population. A patient navigation intervention. Cancer. 2007;109(2 Suppl):359–67.CrossRefGoogle Scholar
  15. 15.
    Freund KM, Battaglia TA, Calhoun E, et al. Impact of patient navigation on timely cancer care: the Patient Navigation Research Program. J Natl Cancer Inst. 2014;106(6):dju115.CrossRefGoogle Scholar
  16. 16.
    Thomas AA, Gallagher P, O’Ceilleachair A, Pearce A, Sharp L, Molcho M. Distance from treating hospital and colorectal cancer survivors’ quality of life: a gendered analysis. Support Care Cancer. 2015;23(3):741–51.CrossRefGoogle Scholar
  17. 17.
    Fazio L, Cotterchio M, Manno M, McLaughlin J, Gallinger S. Association between colonic screening, subject characteristics, and stage of colorectal cancer. Am J Gastroenterol. 2005;100(11):2531–9.CrossRefGoogle Scholar
  18. 18.
    White MG, Applewhite MK, Kaplan EL, Angelos P, Huo D, Grogan RH. A tale of two cancers: traveling to treat pancreatic and thyroid cancer. J Am Coll Surg. 2017;225(1):125–136 e126.CrossRefGoogle Scholar
  19. 19.
    Lidsky ME, Sun Z, Nussbaum DP, Adam MA, Speicher PJ, Blazer DG 3rd. Going the extra mile: improved survival for pancreatic cancer patients traveling to high-volume centers. Ann Surg. 2017;266(2):333–8.CrossRefGoogle Scholar
  20. 20.
    Riall TS, Townsend CM Jr, Kuo YF, Freeman JL, Goodwin JS. Dissecting racial disparities in the treatment of patients with locoregional pancreatic cancer: a 2-step process. Cancer. 2010;116(4):930–9.CrossRefGoogle Scholar
  21. 21.
    Singal V, Singal AK, Kuo YF. Racial disparities in treatment for pancreatic cancer and impact on survival: a population-based analysis. J Cancer Res Clin Oncol. 2012;138(4):715–22.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Laura M. Enomoto
    • 1
  • Joyce Fenstermaker
    • 1
  • Rodwige J. Desnoyers
    • 2
  • Boris C. Pasche
    • 2
  • A. William BlackstockJr.
    • 3
  • Russell M. Howerton
    • 1
  • Clancy J. Clark
    • 1
  • Edward A. Levine
    • 1
  • Perry Shen
    • 1
    Email author
  1. 1.Department of SurgeryWake Forest Baptist Medical CenterWinston SalemUSA
  2. 2.Department of MedicineWake Forest Baptist Medical CenterWinston SalemUSA
  3. 3.Department of RadiologyWake Forest Baptist Medical CenterWinston SalemUSA

Personalised recommendations